Pricing & Reimbursement in Europe: Can the drive for cost effectiveness overcome cost containment?

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-10-04

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Combined drug sales in the five major European markets represent the second-biggest market globally after the US. Unlike the US, which is dominated by a wide range of private payers, governments are the major payers in Europe. The monopsonistic nature of these markets provides governments with significant leverage and they use extensive P&R controls to contain spiralling healthcare costs.


Scope

  • Evaluation of the pressures facing the drugs industry and how these pressures will impact P&R
  • Overview of global P&R controls, examining which are important in the European market both currently and in the future
  • In-depth analysis of each of the five major European markets, examining both the healthcare systems and the key P&R infrastructure
  • Identification of trends and recommendations shaping the European P&R environment


    • Report Highlights
    Better dialogue between healthcare providers and drugs companies is vital; however, healthcare provider devolution has led to fragmentation of the key European markets, making it difficult to identify key P&R stakeholders

    Many European governments profess to be willing to reward innovative drugs, however this is largely a smokescreen as debt-ridden governmental payers increasingly prioritize cost containment

    European drug developers need to prioritize P&R as an important factor in drug development, and focus on securing strong P&R justification before green-lighting me-too drugs


    Reasons to Purchase

  • Gain a clear understanding of the healthcare market dynamics and P&R environment within each of the five major European healthcare markets
  • Review P&R trends in Europe, based on Datamonitor's analysis and primary research conducted with key stakeholders in the industry
  • Gain insight into how P&R fits into company strategy and understand how specific P&R trends are shaping the European markets

    • Table of Contents

    Other users found this report page using the following search terms: pharmacy pharmaceutical company discount schemes pricing reimbursement conferences

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.